Clinical trial
A Randomized, Single-Dose, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
NCT05321602 is registered in ClinicalTrials.gov with Luye Pharma Group Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Single-Dose, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
- Lead sponsor
- Luye Pharma Group Ltd.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 8, 2021
- Completion date
- October 23, 2022
- Enrollment
- 89 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.
antipsychotic agents, central nervous system depression, mental disorders, molecular mechanisms of pharmacological action, mood disorders, neurotransmitter agents, physiological effects of drugs, psychotic disorders, psychotropic drugs, schizophrenia, schizophrenia spectrum and other psychotic disorders, tranquilizing agents